IMCD Buys Australian Ingredients Distributor

IMCD Buys Australian Ingredients Distributor
IMCD Buys Australian Ingredients Distributor
IMCD has bought Sydney-based drug and food ingredient distributor Capitol Ingredients Australia to increase its access to local markets.

The deal – terms of which were not disclosed – also provides Holland-headquartered distributor IMCD with a laboratory at which customers can conduct formulation development and testing.

Capitol’s core customer based is in Australia and New Zealand, which is where it will continue to focus after it is merged with the firm’s personal care unit and established as a separate division of IMCD ANZ.

The takeover comes just a few months​ after IMCD bought Indian pharmaceutical excipients production and distribution company, Indchem.

And, just a few months prior to that the firm bought the pharmaceutical ingredients business of Malaysian ingredient and excipient distributor Maxwell Pharma. It also follows a little over a year after the Netherlands firm bought Italian fine chemicals supplier Organotec .

These deals, coupled with the acquisition of South Africa’s Ethnichem in summer 2011 and the Indchem takeover, underline IMCD’s desire to establish a bigger presence in the pharmaceutical industry.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars